Research Topics
| Charles HicksSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Raltegravir: the first HIV type 1 integrase inhibitorCharles Hicks
Duke University Medical Center, Weill Medical College of Cornell University, Durham, North Carolina 27710, USA
Clin Infect Dis 48:931-9. 2009..As an antiretroviral drug with a novel mechanism of action, raltegravir is an important advancement in HIV-1 treatment options...- Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistaCharles B Hicks
Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA
Lancet 368:466-75. 2006.... - New antiretroviral drugsKimberly Hanson
Duke University Medical Center, Division of Infectious Diseases and International Health, Box 3879, Durham, NC 27710, USA
Curr HIV/AIDS Rep 3:93-101. 2006..We also summarize new classes of antiretroviral therapy in clinical development including the attachment inhibitors, chemokine receptor antagonists, integrase inhibitors, and maturation inhibitors... - Impact of HIV protease inhibitor resistance in treatment-naive populations in the united statesCharles Hicks
Duke University Medical Center, Durham, NC, USA
AIDS Read 15:683-6, 689-90. 2005.... - Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan
Department of Medicine, Duke University Medical Center, Durham, NC 22710, USA
AIDS Res Hum Retroviruses 21:13-6. 2005..Thus, CD4(+)/VL discordance can be maintained for periods exceeding 5 years in some patients receiving PI-based HAART without significant evolution of HIV resistance... - Lopinavir/ritonavir in the treatment of human immunodeficiency virus infectionSusan S Kaplan
Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina, USA
Expert Opin Pharmacother 6:1573-85. 2005..De novo development of resistance has not been described in large clinical trials with patients naive to antiretroviral therapy. Lopinavir/ritonavir has recently been approved for once-daily dosing in antiretroviral-naive patients... - In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthXiaoying Shen
Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA
J Virol 83:3617-25. 2009..Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection... - Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up studyCharles Hicks
Duke University Medical Center, Durham, North Carolina, 27710, USA
AIDS 18:775-9. 2004..The most common adverse events were gastrointestinal symptoms and lipid elevations. CONCLUSIONS: LPV/r-based therapy provides durable antiretroviral response and is generally well tolerated through 204 weeks of therapy... - Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the optionsSusanna Naggie
Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
J Antimicrob Chemother 65:1094-9. 2010..Here, we discuss the current recommendations and recent guidelines, and the evidence available for various PI-based ART regimens in treatment-naive patients. We also discuss adverse effects and the use of PIs in special circumstances... - Current management challenges in HIV: tolerability of antiretrovirals and metabolic complicationsCharles Hicks
Duke University Medical Center, Durham, North Carolina 27710, USA
AIDS Patient Care STDS 17:221-33. 2003..Long-term success requires therapy to be individualized, carefully balancing toxicities with efficacy and resistance... - Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras
Duke Human Vaccine Institute, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Virol 82:12449-63. 2008..These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection... - Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infectionS Munir Alam
Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
J Virol 82:115-25. 2008.... - Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatmentJia Liu
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
Antimicrob Agents Chemother 55:1114-9. 2011..Additional studies in larger populations are warranted to fully understand the clinical implications of these mutations... - Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758Charles B Hicks
Department of Medicine, Duke University, Durham, North Carolina 27710, USA
AIDS Res Hum Retroviruses 25:395-403. 2009..48 mg/dl). In conclusion, through 96 weeks, FPV/r100 was more effective and prompted less elevation in triglycerides than FPV/r200... - HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infectionMattia Bonsignori
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
J Immunol 183:2708-17. 2009..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine... - Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus functionGregory D Sempowski
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
J Clin Immunol 25:462-72. 2005.... - Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Infect Dis 187:1027-37. 2003..These findings suggest that discordant responses may be related to enhanced HIV-directed immune responses, diminished cellular activation, decreased viral replication capacity, and preservation of non-syncytium-inducing virus strains... - Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infectionSusan S Kaplan
Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Antimicrob Chemother 56:273-6. 2005..Current antiretroviral therapy guidelines list lopinavir/ritonavir as the consensus first-line protease inhibitor recommended in the initial therapeutic regimen in persons infected with HIV-1... - Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysisPaul R Bohjanen
Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Antimicrob Agents Chemother 46:2387-92. 2002..Pharmacokinetic modeling suggests that a lamivudine dose of 25 mg daily in hemodialysis subjects would provide serum exposure similar to that provided by a dose of 150 mg twice daily in patients with normal renal function... - Primary human immunodeficiency virusBabafemi O Taiwo
Early Intervention Clinic, Lincoln Health Center, Durham, NC 27707, USA
South Med J 95:1312-7. 2002..The current approach to management of primary HIV infection is based more on expert opinion than clinical trial results, though ongoing clinical trials should provide more information about this syndrome... - Detection of minor drug-resistant populations by parallel allele-specific sequencingFangping Cai
Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Nat Methods 4:123-5. 2007..This assay may serve as a useful tool to study drug resistance in HIV and other infectious agents... - Late diagnosis of HIV infection: the role of age and sexMichael J Mugavero
Division of Infectious Diseases and International Health, Department of Medicine, University of Alabama at Birmingham, USA
Am J Med 120:370-3. 2007..Additionally, we evaluated factors associated with HIV infection being diagnosed during hospitalization... - Lipid changes associated with antiretroviral therapy: results differ by reporting approachWanda Lakey
Division of Endocrinology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
Curr HIV Res 7:547-54. 2009..Implementing a standard approach to reporting lipids including use of NCEP Guidelines and the Framingham risk-prediction model may provide more useful data for clinicians... - Does antiretroviral therapy prevent HIV transmission to sexual partners?Tahaniyat Lalani
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, 34225 Hospital South, Durham, NC 27710, USA
Curr HIV/AIDS Rep 4:80-5. 2007.... - Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settingsAmy C Weintrob
Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
Arch Intern Med 163:2097-100. 2003..Human immunodeficiency virus is infrequently diagnosed during primary infection. More expeditious diagnosis of human immunodeficiency virus infection is a clinical and public health imperative... - Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patientsRobert L Murphy
Northwestern University, Chicago, Illinois, USA
HIV Clin Trials 9:1-10. 2008..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients... - Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infectionStephanie A Freel
School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
AIDS 17:2025-33. 2003..These findings suggest that the oral cavity may serve as an easily accessible surrogate model for studying the dynamics of HIV-1 shedding at mucosal sites... - Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United StatesKit N Simpson
Medical University of South Carolina, Charleston, South Carolina 29425, USA
HIV Clin Trials 9:225-37. 2008.... - Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1Kimberly Ritola
University of North Carolina at Chapel Hill, 22-062 Lineberger Cancer Center, CB 7295, Chapel Hill, NC 27599-7295, USA
J Virol 78:11208-18. 2004..Alternatively, the inefficient transfer of a multiply infected cell could account for both the low probability of transmission and the transfer of multiple variants... - Meeting notes from the 3rd IAS Conference. Old drugs, new dataCharles B Hicks
AIDS Clin Care 17:94-5. 2005..Researchers reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation... - Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scoresSharon L Walmsley
Toronto General Hospital, University of Toronto, Toronto, Canada
AIDS 21:2245-8. 2007..Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir... - Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysisJeffrey P Nadler
Hillsborough County Health Department, University of South Florida, Tampa, FL 33602, USA
AIDS 21:F1-10. 2007.... - Antiretroviral rounds. Entrance left: the endocrinologistCharles B Hicks
AIDS Clin Care 18:18-9. 2006 - Report from the XVI International AIDS Conference. Integrase inhibitorsCharles B Hicks
AIDS Clin Care 18:101. 2006 - Report from the 12th Retrovirus Conference. Acute and recent HIV infectionCharles B Hicks
AIDS Clin Care 17:33-4. 2005 - Report from the 13th retrovirus conference. Integrase inhibitors on the wayCharles B Hicks
AIDS Clin Care 18:33-4. 2006 - Report from the 13th retrovirus conference. New data on TMC114 and TMC125Charles B Hicks
AIDS Clin Care 18:34. 2006 - Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing populationChristopher D Pilcher
Department of Medicien, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7030, USA
JAMA 288:216-21. 2002..However, HIV nucleic acid-based testing is widely used to screen for antibody-negative acute infection among low-risk blood donors... - Diagnosing primary HIV infectionChristopher D Pilcher
Ann Intern Med 136:488-9; author reply 488-9. 2002 - Confronting the clinical uncertainty regarding syphilisCharles B Hicks
AIDS Clin Care 15:64-5. 2003 - Guideline watch. Antiretroviral drug resistance testing--updated guidelines from the IAS-USACharles B Hicks
AIDS Clin Care 20:64. 2008 - Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistanceBabafemi O Taiwo
Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
AIDS Read 17:151-6, 159-61. 2007..In vitro, the coexistence of numerous PI mutations was required for its virological potency to be significantly reduced. Preliminary findings suggest that it is active against some tipranavir-resistant strains... - Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Acyclovir to prevent HIV infection?Charles B Hicks
AIDS Clin Care 19:84-5. 2007 - Unsuspected HIV infection in patients presenting with acute meningitisKimberly E Hanson
Clin Infect Dis 47:433-4. 2008
Research Grants
- INTERDISCIPLINARY RESEARCH TRAINING PROGRAM IN AIDSCharles Hicks; Fiscal Year: 2007..led by Kent Weinhold, PhD; 3) HIV Pathogenesis led by Bryan Cullen, PhD; 4) Acute HIV Infection led by Charles Hicks, MD; 5) HIV-associated Opportunistic Infections led by Carol Hamilton, MD 6) Pediatric HIV led by Coleen ..
- Midcareer Investigator Award /Patient-Oriented ResearchCharles Hicks; Fiscal Year: 2007DESCRIPTION (provided by applicant):The candidate, Charles Hicks, seeks to enhance his capabilities in mentoring new investigators in the conduct of patient-oriented clinical research in Human Immunodeficiency Virus (HIV) infection...